ATRX and central nervous system cancer: Moreover, mice harboring ATRX-deficient gliomas in the context of our RCAS/Ntv-a genetically engineered model also exhibited extended survival relative to ATRX-intact counterparts, in both de novo and re-injection contexts (Fig. 2b; Supplementary Fig. 3b, c).